Tower Research Capital LLC (Trc) Gain Therapeutics, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $3.29 Billion
- Q1 2025
A detailed history of Tower Research Capital LLC (Trc) transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 2,432 shares of GANX stock, worth $4,620. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,432Holding current value
$4,620% of portfolio
0.0%Shares
15 transactions
Others Institutions Holding GANX
# of Institutions
37Shares Held
3.1MCall Options Held
8.4KPut Options Held
8.7K-
David Einhorn Greenlight Capital Inc | New York, Ny588KShares$1.12 Million0.1% of portfolio
-
Dme Capital Management, LP New York, NY566KShares$1.08 Million0.05% of portfolio
-
Geode Capital Management, LLC Boston, MA282KShares$536,2000.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA255KShares$484,4810.0% of portfolio
-
Marshall Wace, LLP London, X0196KShares$372,4490.0% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $22.6M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...